OBJECTIVE: This study examined the short-term effects of first- and second-generation antipsychotic medications on social cognition and basic cognition. METHOD: One hundred patients with schizophrenia or schizoaffective disorder participated in an 8 week, double-blind study ofrisperidone, olanzapine, and haloperidol. Participants were administered multiple measures of social cognition, basic cognition, and clinical symptoms at baseline, the end of week 4, and the end of week 8. Seventy-three patients completed the baseline assessment and at least one other assessment. Data were analyzed with mixed-effects analyses of covariance. For data reduction, the social cognitive measures were clustered into a summary score, and the cognitive measures were clustered into two summary scores: general cognitive ability and processing speed. RESULTS: There were no treatment-related differences on any of the three summary scores. Social cognition did not show within-group changes over time either by itself or after control for the cognitive clusters. One cognitive score (general cognitive ability) increased during the study period for all three medication groups. CONCLUSIONS: The present study included a rather thorough assessment of social cognition and did not find any evidence of between-group or within-group effects of antipsychotic medication on social cognition.
RCT Entities:
OBJECTIVE: This study examined the short-term effects of first- and second-generation antipsychotic medications on social cognition and basic cognition. METHOD: One hundred patients with schizophrenia or schizoaffective disorder participated in an 8 week, double-blind study of risperidone, olanzapine, and haloperidol. Participants were administered multiple measures of social cognition, basic cognition, and clinical symptoms at baseline, the end of week 4, and the end of week 8. Seventy-three patients completed the baseline assessment and at least one other assessment. Data were analyzed with mixed-effects analyses of covariance. For data reduction, the social cognitive measures were clustered into a summary score, and the cognitive measures were clustered into two summary scores: general cognitive ability and processing speed. RESULTS: There were no treatment-related differences on any of the three summary scores. Social cognition did not show within-group changes over time either by itself or after control for the cognitive clusters. One cognitive score (general cognitive ability) increased during the study period for all three medication groups. CONCLUSIONS: The present study included a rather thorough assessment of social cognition and did not find any evidence of between-group or within-group effects of antipsychotic medication on social cognition.
Authors: Erin J Wamsley; Ann K Shinn; Matthew A Tucker; Kim E Ono; Sophia K McKinley; Alice V Ely; Donald C Goff; Robert Stickgold; Dara S Manoach Journal: Sleep Date: 2013-09-01 Impact factor: 5.849
Authors: Shaun M Eack; Deborah P Greenwald; Susan S Hogarty; Susan J Cooley; Ann Louise DiBarry; Debra M Montrose; Matcheri S Keshavan Journal: Psychiatr Serv Date: 2009-11 Impact factor: 3.084
Authors: Charlie A Davidson; Danijela Piskulic; Jean Addington; Kristen S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Carrie E Bearden; Daniel H Mathalon; Scott W Woods; Jason K Johannesen Journal: Schizophr Res Date: 2018-05-08 Impact factor: 4.939
Authors: Ingo Frommann; Ralf Pukrop; Jürgen Brinkmeyer; Andreas Bechdolf; Stephan Ruhrmann; Julia Berning; Petra Decker; Michael Riedel; Hans-Jürgen Möller; Wolfgang Wölwer; Wolfgang Gaebel; Joachim Klosterkötter; Wolfgang Maier; Michael Wagner Journal: Schizophr Bull Date: 2010-01-06 Impact factor: 9.306